REG - Hutchmed China Ltd - HUTCHMED to Announce 2024 HY Financial Results

HUTCHMED (China)Announcement

26/06/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240626:nRSZ8111Ta&default-theme=true

RNS Number : 8111T  Hutchmed (China) Limited  26 June 2024

HUTCHMED to Announce 2024 Half-Year Financial Results

 

Hong Kong, Shanghai & Florham Park, NJ - Wednesday, June 26, 2024:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six
months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern
Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong
Time (HKT).

 

Analysts and investors are invited to join a conference call and audio webcast
presentation with Q&A, conducted by HUTCHMED management.

 

The English conference call and audio webcast will be held on Wednesday, July
31, 2024, at 8:00 am EDT (1:00 pm BST / 8:00 pm HKT). The Chinese (Putonghua)
webcast will be held at 8:30 am HKT / 1:30 am BST on Thursday, August 1, 2024
(8:30 pm EDT on Wednesday, July 31, 2024). Both webcasts will be available
live via the company website at www.hutch-med.com/event/
(https://www.hutch-med.com/event/) . The presentation will be available for
downloading before the conference call begins. Details of the conference call
dial-in will be provided in the financial results announcement and on the
company website. A replay will also be available on the website shortly after
the event.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception it has focused on bringing
cancer drug candidates from in-house discovery to patients around the world,
with its first three oncology drugs marketed in China, the first of which is
also marketed in the U.S. For more information, please visit:
www.hutch-med.com (https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

 

CONTACTS
 Investor Enquiries                                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting                              +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                                     +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                     (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                                  +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Gordon   +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFLFLLRIIEFIS